Study of cabotegravir and lenacapavir dual long-acting therapy for HIV
Part of Infections clinical trials.
This trial is studying a two-drug combination (cabotegravir and lenacapavir) given as long-acting shots for people with HIV. If you are already taking or about to start this combination, your doctor may invite you to join so researchers can track how well it works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HIV-1 infection
- You have already started taking the combination of cabotegravir and lenacapavir (CAB/LEN) between July 2024 and one year later, or you are about to start taking it
- Your doctor decided that starting CAB/LEN is the right treatment for you
- You agree to have your follow-up data used for this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well lenacapavir works when added to a personalized HIV treatment plan. If you have HIV and received lenacapavir as your first dose between June 2023 and June 2024, this research may help understand its real-world effects.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
Hear when a new CABOTEGRAVIR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.